436864-53-8

Basic information

• Product Name: methyl 2-(4-aminobutoxy)-6-hydroxybenzoate
• Synonyms: methyl 2-(4-aminobutoxy)-6-hydroxybenzoate
• CAS NO: 436864-53-8
• Molecular Weight: 239.271
• Mol File: 436864-53-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-aminobutoxy)-6-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-aminobutoxy)-6-hydroxybenzoate(436864-53-8)
• EPA Substance Registry System: methyl 2-(4-aminobutoxy)-6-hydroxybenzoate(436864-53-8)

Safety Data

• Hazardous Substances Data: 436864-53-8(Hazardous Substances Data)

Upstream product

• 2150-45-0 methyl 2,6-dihydroxybenzoate 
• 436864-52-7 2-(4-tert-butoxycarbonylaminobutoxy)-6-hydroxybenzoic acid methyl ester 

Downstream Products

• 474917-96-9 methyl 2-(4-{[4-{[(benzyloxy)(oxo)acetyl]amino}-N-(tert-butoxycarbonyl)-L-phenylalanyl]amino}butoxy)-6-hydroxybenzoate 
• 436864-58-3 methyl 2-{4-[(N-[(allyloxy)carbonyl]-4-{{2-[(benzhydryloxy)carbonyl]phenyl}[tert-butoxy(oxo)acetyl]amino}-L-phenylalanyl)amino]butoxy}-6-hydroxybenzoate 
• 918657-87-1 2-{4-[2-acetylamino-3-(4-carboxymethoxy-3-hydroxy-phenyl)-propionylamino]-butoxy}-6-hydroxy-benzoic acid methyl ester 
• 474917-82-3 methyl 2-(4-{[4-amino-N-(tert-butoxycarbonyl)-L-phenylalanyl]amino}butoxy)-6-hydroxybenzoate 
• 474917-81-2 2-{4-[2-tert-butoxycarbonylamino-3-(4-nitro-phenyl)-propionylamino]-butoxy}-6-hydroxy-benzoic acid methyl ester 

Relevant articles and documents

Selective protein tyrosine phosphatatase inhibitors

Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.

Selective protein tyrosine phosphatatase inhibitors

Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.